odemsertib   Click here for help

GtoPdb Ligand ID: 14624

Synonyms: compound 127 [PMID: 37402343] | VI-176 [1-2]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Odemsertib is the INN for a serine/threonine kinase inhibitor that targets IRAK1/4 for immunosuppression effect [1]. It is the active form of the oral prodrug odemsertib etifosfate (R906289; RG289; Rigel Therapeutics). The company code for odemsertib is R835.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 128.34
Molecular weight 499.54
XLogP 2.93
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CCOC1CCC(CC1)N2C=C(C(=N2)C3=NC(=CC=C3F)F)NC(=O)C4=CSC(=N4)C5=CNN=C5
Isomeric SMILES CCOC1CCC(CC1)N2C=C(C(=N2)C3=C(C=CC(=N3)F)F)NC(=O)C4=CSC(=N4)C5=CNN=C5
InChI InChI=1S/C23H23F2N7O2S/c1-2-34-15-5-3-14(4-6-15)32-11-17(21(31-32)20-16(24)7-8-19(25)30-20)28-22(33)18-12-35-23(29-18)13-9-26-27-10-13/h7-12,14-15H,2-6H2,1H3,(H,26,27)(H,28,33)
InChI Key WCFCQFGVNHHQKA-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Bai YR, Yang WG, Hou XH, Shen DD, Zhang SN, Li Y, Qiao YY, Wang SQ, Yuan S, Liu HM. (2023)
The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases.
Eur J Med Chem, 258: 115606. [PMID:37402343]
2. Taylor V, Issakani S, Young C. (2021)
Compounds and method for treating cytokine release syndrome.
Patent number: WO2021026451A1. Assignee: Rigel Pharmaceuticals Inc. Priority date: 07/08/2020. Publication date: 11/02/2021.